Overview
- Researchers at McMaster, working with MIT’s CSAIL, reported enterololin as a potential therapy for inflammatory bowel diseases including Crohn’s.
- The narrow-spectrum compound focuses on Enterobacteriaceae, including harmful E. coli strains implicated in disease.
- AI predicted that enterololin targets the essential LolCDE protein complex in the bacteria within roughly 100 seconds.
- McMaster lab work led by graduate student Denise Catacutan validated the predicted mechanism of action.
- Jon Stokes said the streamlined approach reduced time and cost for MOA work, and his spinout Stoked Bio has licensed the drug for refinement and tests of modified versions against other drug-resistant bacteria.